115 related articles for article (PubMed ID: 37566230)
1. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
[TBL] [Abstract][Full Text] [Related]
2. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
Ando Y; Dbouk M; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Dbouk A; Blackford AL; Lin MT; Lennon AM; Burkhart RA; He J; Sokoll L; Eshleman JR; Canto MI; Goggins M
J Clin Oncol; 2024 Mar; ():JCO2301573. PubMed ID: 38457748
[TBL] [Abstract][Full Text] [Related]
3. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery.
Ando Y; Dbouk M; Blackford AL; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Sokoll L; Eshleman JR; Burkhart R; He J; Goggins M
Ann Surg Oncol; 2024 May; 31(5):2902-2912. PubMed ID: 38319515
[TBL] [Abstract][Full Text] [Related]
4. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
5. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer.
Tanaka H; Tamura K; Abe T; Yoshida T; Macgregor-Das A; Dbouk M; Blackford AL; Borges M; Lennon AM; He J; Burkhart R; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2267-2275.e2. PubMed ID: 34648951
[TBL] [Abstract][Full Text] [Related]
6. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
8. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
9. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
Ben-Ami R; Wang QL; Zhang J; Supplee JG; Fahrmann JF; Lehmann-Werman R; Brais LK; Nowak J; Yuan C; Loftus M; Babic A; Irajizad E; Davidi T; Zick A; Hubert A; Neiman D; Piyanzin S; Gal-Rosenberg O; Horn A; Shemer R; Glaser B; Boos N; Jajoo K; Lee L; Clancy TE; Rubinson DA; Ng K; Chabot JA; Kastrinos F; Kluger M; Aguirre AJ; Jänne PA; Bardeesy N; Stanger B; O'Hara MH; Till J; Maitra A; Carpenter EL; Bullock AJ; Genkinger J; Hanash SM; Paweletz CP; Dor Y; Wolpin BM
Gut; 2024 Mar; 73(4):639-648. PubMed ID: 38123998
[TBL] [Abstract][Full Text] [Related]
10. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
12. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
[TBL] [Abstract][Full Text] [Related]
15. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
16. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
17. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
20. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
